These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 22027693)
1. A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Allen WL; Stevenson L; Coyle VM; Jithesh PV; Proutski I; Carson G; Gordon MA; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG Mol Cancer Ther; 2012 Jan; 11(1):119-31. PubMed ID: 22027693 [TBL] [Abstract][Full Text] [Related]
2. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Zhou Y; Bollu LR; Tozzi F; Ye X; Bhattacharya R; Gao G; Dupre E; Xia L; Lu J; Fan F; Bellister S; Ellis LM; Weihua Z Mol Cancer Ther; 2013 Dec; 12(12):2782-91. PubMed ID: 24132143 [TBL] [Abstract][Full Text] [Related]
3. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Allen WL; Coyle VM; Jithesh PV; Proutski I; Stevenson L; Fenning C; Longley DB; Wilson RH; Gordon M; Lenz HJ; Johnston PG Clin Cancer Res; 2008 Oct; 14(20):6647-55. PubMed ID: 18927307 [TBL] [Abstract][Full Text] [Related]
4. Irinotecan/5-fluorouracil combination induces alterations in mitochondrial membrane potential and caspases on colon cancer cell lines. Grivicich I; Regner A; da Rocha AB; Grass LB; Alves PA; Kayser GB; Schwartsmann G; Henriques JA Oncol Res; 2005; 15(7-8):385-92. PubMed ID: 16491956 [TBL] [Abstract][Full Text] [Related]
6. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells. Allen WL; Turkington RC; Stevenson L; Carson G; Coyle VM; Hector S; Dunne P; Van Schaeybroeck S; Longley DB; Johnston PG Mol Cancer Ther; 2012 Aug; 11(8):1724-34. PubMed ID: 22665525 [TBL] [Abstract][Full Text] [Related]
8. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Gongora C; Candeil L; Vezzio N; Copois V; Denis V; Breil C; Molina F; Fraslon C; Conseiller E; Pau B; Martineau P; Del Rio M Cancer Biol Ther; 2008 Jun; 7(6):822-32. PubMed ID: 18340113 [TBL] [Abstract][Full Text] [Related]
9. New Topoisomerase I mutations are associated with resistance to camptothecin. Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602 [TBL] [Abstract][Full Text] [Related]
10. A nanotherapeutic strategy to overcome chemoresistance to irinotecan/7-ethyl-10-hydroxy-camptothecin in colorectal cancer. Huang Q; Liu X; Wang H; Liu X; Zhang Q; Li K; Chen Y; Zhu Q; Shen Y; Sui M Acta Biomater; 2022 Jan; 137():262-275. PubMed ID: 34718178 [TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer. Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538 [TBL] [Abstract][Full Text] [Related]
12. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. Camp ER; Li J; Minnich DJ; Brank A; Moldawer LL; MacKay SL; Hochwald SN J Am Coll Surg; 2004 Aug; 199(2):249-58. PubMed ID: 15275881 [TBL] [Abstract][Full Text] [Related]
13. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084 [TBL] [Abstract][Full Text] [Related]
14. in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Inoue Y; Tanaka K; Hiro J; Yoshiyama S; Toiyama Y; Eguchi T; Miki C; Kusunoki M Int J Oncol; 2006 Feb; 28(2):479-86. PubMed ID: 16391804 [TBL] [Abstract][Full Text] [Related]
15. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Fischel JL; Rostagno P; Formento P; Dubreuil A; Etienne MC; Milano G Br J Cancer; 2001 Feb; 84(4):579-85. PubMed ID: 11207057 [TBL] [Abstract][Full Text] [Related]
16. Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. Plasencia C; Abad A; Martinez-Balibrea E; Taron M Invest New Drugs; 2004 Nov; 22(4):399-409. PubMed ID: 15292710 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Crea F; Giovannetti E; Cortesi F; Mey V; Nannizzi S; Gallegos Ruiz MI; Ricciardi S; Del Tacca M; Peters GJ; Danesi R Mol Cancer Ther; 2009 Jul; 8(7):1964-73. PubMed ID: 19531575 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. Zhang Y; Talmon G; Wang J Cell Death Dis; 2015 Aug; 6(8):e1845. PubMed ID: 26247730 [TBL] [Abstract][Full Text] [Related]
19. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. Kuebler JP; de Gramont A Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794 [TBL] [Abstract][Full Text] [Related]
20. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer. Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]